Stratifying Patients for Targeted Immunotherapy Response

59 concepts60 papers1 proposal

Modern immunotherapies, such as immune checkpoint inhibitors (ICIs), have revolutionized oncology by shifting the therapeutic target from the tumor itself to the patient’s own immune system. By blocking inhibitory pathways like PD-1/PD-L1 or CTLA-4, these drugs unleash T cells to destroy malignancies. Yet, a profound clinical paradox remains: while a minority of patients experience durable, life-saving remissions, the majority derive no clinical benefit while remaining exposed to severe toxicities and high financial costs.

To resolve this variability, researchers are developing predictive biomarkers designed to stratify patients before treatment begins. The core intuition behind this direction is that a drug cannot successfully activate an immune response if the underlying biological machinery is missing, blocked, or systemically exhausted. By mapping the baseline state of the tumor microenvironment (TME) and systemic circulation, clinicians can predict whether the therapeutic "spark" will catch fire.

The Cellular Battlefield: Hot versus Cold Microenvironments

To understand why a checkpoint inhibitor succeeds or fails, we must look at the spatial and cellular composition of the tumor microenvironment. Checkpoint inhibitors do not kill cancer cells directly; they merely remove the molecular "brakes" from pre-existing T cells. If a tumor completely lacks immune cell infiltration—a state known as a "cold" tumor—removing the brakes has no therapeutic effect because there are no cellular soldiers on the battlefield. Conversely, "hot" tumors are already highly infiltrated by T cells that have simply been paralyzed by the tumor's defense mechanisms.

To capture this dynamic, researchers look for gene signatures that reflect active immune infiltration. For instance, Nan Hu et al. demonstrated in An Immune-Related Prognostic Signature Predicts Overall Survival in Stomach Adenocarcinomas that a compact three-gene signature (PEG10, DKK1, and RGS1) can effectively categorize tumors into hot and cold phenotypes, serving as a reliable proxy for immunotherapy readiness.

However, cellular presence alone is not always sufficient. The physical architecture of the tumor can create structural barriers that prevent immune cells from reaching their targets. Sen Guo et al. addressed this in Re-Clustering and Profiling of Digestive System Tumors According to Microenvironment Components, showing that high "stromal scores"—which measure non-tumor structural cells and extracellular matrix components—strongly correlate with poor immunotherapy response. In these cases, even if the immune system is primed, the dense physical matrix acts as a shield, rendering checkpoint blockade ineffective.

Furthermore, resistance can be driven by active cellular transformations within the tumor. In a large-scale clinical setting, Dean A. Fennell et al. analyzed the Phase III CONFIRM trial in Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial. They discovered that while durable sensitivity to the PD-1 inhibitor nivolumab is driven by localized, B-cell-rich tertiary lymphoid structures, therapeutic resistance is dictated by epithelial-mesenchymal transition (EMT)—a process where tumor cells morphologically transform to evade immune detection and physical infiltration.

Proxies of Immune Readiness

Because directly sequencing the entire tumor microenvironment for every patient is resource-intensive, researchers look for specific surface proteins or intracellular regulators that act as reliable proxies for the tumor's overall immune state.

One such proxy is CD74, a protein traditionally known for its role as a chaperone for major histocompatibility complex (MHC) class II molecules. D Chen et al. identified in CD74 is a potential biomarker predicting the response to immune checkpoint blockade that high CD74 expression serves as a robust pan-cancer indicator of a "hotter" tumor microenvironment. Because CD74 is intrinsically tied to the antigen presentation pathway, its abundance signals that the tumor is actively presenting foreign antigens to the immune system, making it an ideal target for checkpoint inhibitors.

Similarly, alternative immune checkpoints can provide a more accurate reflection of immune exhaustion than standard PD-L1 staining alone. In Exploration of the Prognostic and Immunotherapeutic Value of B and T Lymphocyte Attenuator in Skin Cutaneous Melanoma, Xubin Dong et al. demonstrated that the expression of B and T lymphocyte attenuator (BTLA) tracks the presence of mature, targetable immune infiltrates more precisely than conventional markers, offering a superior predictive accuracy for anti-PD-1 therapies.

Systemic Windows: Reading the Peripheral Echo

While tissue-based biomarkers provide a direct look at the tumor site, they suffer from a major clinical limitation: tumors are spatially heterogeneous, and obtaining repeated tissue biopsies is highly invasive. To circumvent this, a major facet of this research direction focuses on peripheral biomarkers—reading the systemic "echo" of the tumor's immune interaction within blood or bodily fluids.

The intuition here is that a localized immune battle alters systemic circulation. Chronic, tumor-induced inflammation can exhaust the host's immune reservoir, which manifests as distinct signatures in peripheral blood. For example, Baoyue Pan et al. demonstrated in The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors that elevated levels of C-reactive protein (CRP) and specific circulating inflammatory cytokines (such as MCP-1 and TNF-α) serve as independent predictors of progression-free survival. This systemic inflammatory tone was mirrored in cervical cancer cohorts studied by Mingxiu Ju et al. in The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer, confirming that a hyper-inflamed systemic baseline often correlates with poor therapeutic outcomes.

Beyond individual proteins, the gene expression profiles of circulating immune cells themselves can reveal whether the patient's immune system is capable of mounting a response. Benita Wolf et al. isolated peripheral blood lymphocytes (PBLs) in Gene Expression Profile of Peripheral Blood Lymphocytes from Renal Cell Carcinoma Patients Treated with IL-2, Interferon-α and Dendritic Cell Vaccine and found that the molecular signatures of these circulating cells accurately differentiate responders from non-responders, capturing the delicate systemic balance between immune activation and regulation before any therapeutic agents are administered.

Multi-Omic Integration and Radiotranscriptomics

Because cancer biology is inherently non-linear, single-gene or single-protein markers often fail to capture the full picture of therapeutic resistance. The field is therefore moving toward multi-dimensional computational models that integrate diverse biological layers—such as genomics, transcriptomics, and even macroscopic imaging—to generate highly accurate risk scores.

By focusing on upstream epigenetic regulators rather than downstream genes, researchers can capture broader shifts in cellular state. Yuancheng Huang et al. leveraged this approach in Identification of N6-Methylandenosine-Related lncRNAs for Subtype Identification and Risk Stratification in Gastric Adenocarcinoma, constructing a 14-lncRNA signature based on $m^6A$ RNA modification pathways. This model successfully maps out distinct patient subtypes and predicts their sensitivity to immunotherapy by capturing the overarching epigenetic wiring of the tumor.

[Macroscopic Imaging: DCE-MRI] ──(Radiotranscriptomic Mapping)──> [Microscopic TME: Gene Expression] ──> [Response Prediction]

Perhaps the most intuitive leap in non-invasive stratification is the emergence of radiotranscriptomics, which bridges the gap between macroscopic radiology and microscopic molecular biology. In A predictive radiotranscriptomics model based on DCE-MRI for tumor immune landscape and immunotherapy in cholangiocarcinoma, Lu Chen et al. developed a model that maps specific contrast-enhancement patterns from routine dynamic contrast-enhanced MRI (DCE-MRI) scans directly to underlying immune gene expression profiles. By training a model to recognize the macroscopic imaging "fingerprints" of a highly vascularized, immune-hot tumor, the authors demonstrated that clinicians can non-invasively predict a patient's likelihood of responding to immunotherapy without needing a physical tissue sample.

History & citationVersion 1 · 2026-10-04

Current · Permanent link

View frozen version 1

Cite this direction

Latest version (a living page):

@misc{lacuna_predictive_biomarker_identification_472a5db4,
  title = {predictive biomarker identification},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/predictive-biomarker-identification/rdr_472a5db4dd1c41cfaa8b0286a8c3f3e3},
  note = {Latest version of a living research direction; cite a version for a fixed text. Accessed 2026-11-20},
}

This exact version (version 1, frozen text):

@misc{lacuna_predictive_biomarker_identification_472a5db4_v1,
  title = {predictive biomarker identification},
  author = {{Lacuna}},
  howpublished = {Lacuna research direction},
  year = {2026},
  url = {https://lacuna.tiptreesystems.com/direction/predictive-biomarker-identification/rdr_472a5db4dd1c41cfaa8b0286a8c3f3e3/v/1},
  note = {Version 1, frozen 2026-10-04. Accessed 2026-11-20},
}
About

These directions overlap with this one through shared papers.

See something wrong? Report a mistake